Back to Search

Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

Recruiting Observational Study
Lung Cancer
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
2,000 (estimated)
Sponsor
AstraZeneca · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosed stage IB-III NSCLC on or prior to the index date; * Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026
Contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

CONTACT

NCT ID: NCT07593248 Source: ClinicalTrials.gov